FDA endorses new regimen for deadly drug-resistant tuberculosis rampant in developing world
The bacteria behind tuberculosis do not discriminate — they are all-pervasive, but the highest burden of disease is borne by poorer nations. Like many other forms of bacteria, TB-causing bacteria have rapidly mutated to become drug-resistant — and for those inflicted with these strains, options are limited and prognosis feeble. In a first, the FDA on Wednesday approved a three-drug cocktail developed by a nonprofit organization that is engineered to help those with the stubborn form of TB that has failed to respond to conventional therapy.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.